The anticancer capacity of ursolic acid (UA) has been demonstrated, both in vitro and in vivo, in several cancer cell lines (the gastric cancer line, BGC-803, and the hepatocellular cancer H22 xenograft), activating both the pathway intrinsic apoptotic pathway as well as the extrinsic apoptotic pathway, modifying most of the molecular markers involved in them, such as cellular arrest in the G0/G1 phase, DNA fragmentation, an increase in the activities of caspases-3, caspase-8 and caspase-9, as well as downregulation of antiapoptotic proteins such as Bcl-2 [130,131]. This evidence concerns the gene BCL2 and cancer.